Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Moderna ( (MRNA) ) just unveiled an update.

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to ...

Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to support financial flexibility and ...

President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, ...

With much of Moderna’s recent rise tied to its COVID-19 vaccine, the company has struggled to match the sales highs it ...

Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company ...

Moderna's chief technical operations officer explains why now is the right time to take full control of the company's ...

Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management, as it targets up to 10% revenue ...

Boston-based Moderna has been the S&P 500’s most shorted stock since the end of September, according to S3 Partners. Short ...

In today’s Pharmaceutical Executive Daily, Novo Nordisk faces market pressure after a late-stage trial setback, Moderna takes ...

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.

Moderna closed a five-year term loan facility for up to $1.5 billion of capital from Ares Management Credit Funds (Ares) to increase flexibility. The non-dilutive debt financing consists of three ...